SynthesisClinical and experimental medicine2025
Periostin and rheumatic diseases: early insights from a systematic review and meta-analysis.
Synthesis in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Spatial patterning of fibroblast TGFβ signaling underlies treatment resistance in rheumatoid arthritis.Nature immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Periostin regulates angiogenesis, inflammation, and fibrosis, key processes in the pathophysiology of rheumatic diseases (RDs). However, its association with RDs has not been assessed. We conducted a systematic review and meta-analysis of studies reporting circulating periostin in RD patients and healthy controls. We searched electronic databases from inception to 30 November 2024 for relevant articles and assessed the risk of bias and the certainty of evidence using the JBI critical appraisal checklist and GRADE, respectively. In 12 eligible studies, there was a non-significant trend towards higher periostin concentrations in RD patients (standard mean difference, SMD = 0.46, 95% CI -0.07 to 0.98, p = 0.089; I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.